A trial of recombinant α2 interferon in the myelodysplastic syndromes

I. Clinical results

L. Elias, R. Hoffman, H. Boswell, L. Tensen, E. M. Bonnem

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Interferon has been reported to have differentiation promoting effects in certain model systems. Because of this and other potentially beneficial effect, a trial of recombinant α2 interferon was undertaken in myelodysplastic syndromes. The study population consisted of 14 patients, subclassified as two refractory anemia (RA), one RA with ring sideroblasts (RARS), nine RA with excess blasts (RAEB), and two chronic myelomonocytic leukemia (CMMoL). The planned dosage schedule was 2.0 MU/M2 t.i.w. sc x 2 weeks q 4 weeks for at least two cycles. No patient achieved the prospective remission criteria, which included sustained blood count improvements. Transient improvements of platelet counts of >50% in baseline were noted in six patients, and a transient antileukemic effect was noted in one patient with CMMoL. Myelodysplastic syndrome patients were found to be sensitive to the count suppressing effects of α2 interferon with >25% suppression of granulocytes, platelets, or reticulocytes transiently noted in 11 patients and decreasing bone marrow cellularity noted in two while on treatment. Because of these effects, dosage adjustments were frequently instituted in the RA, RARS, and RAEB patients. The average dosages and durations of treatment received were thus 1.48 MU/M2 x 19.4 injections for patients with RA, RARS, and RAEB and 2.25 MU/M2 x 27 injections for the CMMoL patients. Progression to acute myeloid leukemia or RAEB in transformation was noted in five patients, and increasing leukocytosis was noted in one CMMoL patient while on protocol. It cannot be determined at this time whether these transformations were accelerated by α2 interferon or represent selection bias in this study population. Although some evidence of beneficial effects was noted, α2 interferon in this dosage and schedule is not a useful treatment for myelodysplastic syndromes.

Original languageEnglish (US)
Pages (from-to)105-110
Number of pages6
JournalLeukemia
Volume1
Issue number2
StatePublished - 1987
Externally publishedYes

Fingerprint

Myelodysplastic Syndromes
Interferons
Leukemia, Myelomonocytic, Chronic
Refractory Anemia
Appointments and Schedules
Refractory Anemia with Excess of Blasts
Injections
Selection Bias
Reticulocytes
Leukocytosis
Lymphocyte Activation
Platelet Count
Granulocytes
Acute Myeloid Leukemia
Population
Therapeutics
Blood Platelets
Bone Marrow

ASJC Scopus subject areas

  • Cancer Research
  • Hematology

Cite this

Elias, L., Hoffman, R., Boswell, H., Tensen, L., & Bonnem, E. M. (1987). A trial of recombinant α2 interferon in the myelodysplastic syndromes: I. Clinical results. Leukemia, 1(2), 105-110.

A trial of recombinant α2 interferon in the myelodysplastic syndromes : I. Clinical results. / Elias, L.; Hoffman, R.; Boswell, H.; Tensen, L.; Bonnem, E. M.

In: Leukemia, Vol. 1, No. 2, 1987, p. 105-110.

Research output: Contribution to journalArticle

Elias, L, Hoffman, R, Boswell, H, Tensen, L & Bonnem, EM 1987, 'A trial of recombinant α2 interferon in the myelodysplastic syndromes: I. Clinical results', Leukemia, vol. 1, no. 2, pp. 105-110.
Elias, L. ; Hoffman, R. ; Boswell, H. ; Tensen, L. ; Bonnem, E. M. / A trial of recombinant α2 interferon in the myelodysplastic syndromes : I. Clinical results. In: Leukemia. 1987 ; Vol. 1, No. 2. pp. 105-110.
@article{22dd2f8e663b4e0380b201e9cba72755,
title = "A trial of recombinant α2 interferon in the myelodysplastic syndromes: I. Clinical results",
abstract = "Interferon has been reported to have differentiation promoting effects in certain model systems. Because of this and other potentially beneficial effect, a trial of recombinant α2 interferon was undertaken in myelodysplastic syndromes. The study population consisted of 14 patients, subclassified as two refractory anemia (RA), one RA with ring sideroblasts (RARS), nine RA with excess blasts (RAEB), and two chronic myelomonocytic leukemia (CMMoL). The planned dosage schedule was 2.0 MU/M2 t.i.w. sc x 2 weeks q 4 weeks for at least two cycles. No patient achieved the prospective remission criteria, which included sustained blood count improvements. Transient improvements of platelet counts of >50{\%} in baseline were noted in six patients, and a transient antileukemic effect was noted in one patient with CMMoL. Myelodysplastic syndrome patients were found to be sensitive to the count suppressing effects of α2 interferon with >25{\%} suppression of granulocytes, platelets, or reticulocytes transiently noted in 11 patients and decreasing bone marrow cellularity noted in two while on treatment. Because of these effects, dosage adjustments were frequently instituted in the RA, RARS, and RAEB patients. The average dosages and durations of treatment received were thus 1.48 MU/M2 x 19.4 injections for patients with RA, RARS, and RAEB and 2.25 MU/M2 x 27 injections for the CMMoL patients. Progression to acute myeloid leukemia or RAEB in transformation was noted in five patients, and increasing leukocytosis was noted in one CMMoL patient while on protocol. It cannot be determined at this time whether these transformations were accelerated by α2 interferon or represent selection bias in this study population. Although some evidence of beneficial effects was noted, α2 interferon in this dosage and schedule is not a useful treatment for myelodysplastic syndromes.",
author = "L. Elias and R. Hoffman and H. Boswell and L. Tensen and Bonnem, {E. M.}",
year = "1987",
language = "English (US)",
volume = "1",
pages = "105--110",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - A trial of recombinant α2 interferon in the myelodysplastic syndromes

T2 - I. Clinical results

AU - Elias, L.

AU - Hoffman, R.

AU - Boswell, H.

AU - Tensen, L.

AU - Bonnem, E. M.

PY - 1987

Y1 - 1987

N2 - Interferon has been reported to have differentiation promoting effects in certain model systems. Because of this and other potentially beneficial effect, a trial of recombinant α2 interferon was undertaken in myelodysplastic syndromes. The study population consisted of 14 patients, subclassified as two refractory anemia (RA), one RA with ring sideroblasts (RARS), nine RA with excess blasts (RAEB), and two chronic myelomonocytic leukemia (CMMoL). The planned dosage schedule was 2.0 MU/M2 t.i.w. sc x 2 weeks q 4 weeks for at least two cycles. No patient achieved the prospective remission criteria, which included sustained blood count improvements. Transient improvements of platelet counts of >50% in baseline were noted in six patients, and a transient antileukemic effect was noted in one patient with CMMoL. Myelodysplastic syndrome patients were found to be sensitive to the count suppressing effects of α2 interferon with >25% suppression of granulocytes, platelets, or reticulocytes transiently noted in 11 patients and decreasing bone marrow cellularity noted in two while on treatment. Because of these effects, dosage adjustments were frequently instituted in the RA, RARS, and RAEB patients. The average dosages and durations of treatment received were thus 1.48 MU/M2 x 19.4 injections for patients with RA, RARS, and RAEB and 2.25 MU/M2 x 27 injections for the CMMoL patients. Progression to acute myeloid leukemia or RAEB in transformation was noted in five patients, and increasing leukocytosis was noted in one CMMoL patient while on protocol. It cannot be determined at this time whether these transformations were accelerated by α2 interferon or represent selection bias in this study population. Although some evidence of beneficial effects was noted, α2 interferon in this dosage and schedule is not a useful treatment for myelodysplastic syndromes.

AB - Interferon has been reported to have differentiation promoting effects in certain model systems. Because of this and other potentially beneficial effect, a trial of recombinant α2 interferon was undertaken in myelodysplastic syndromes. The study population consisted of 14 patients, subclassified as two refractory anemia (RA), one RA with ring sideroblasts (RARS), nine RA with excess blasts (RAEB), and two chronic myelomonocytic leukemia (CMMoL). The planned dosage schedule was 2.0 MU/M2 t.i.w. sc x 2 weeks q 4 weeks for at least two cycles. No patient achieved the prospective remission criteria, which included sustained blood count improvements. Transient improvements of platelet counts of >50% in baseline were noted in six patients, and a transient antileukemic effect was noted in one patient with CMMoL. Myelodysplastic syndrome patients were found to be sensitive to the count suppressing effects of α2 interferon with >25% suppression of granulocytes, platelets, or reticulocytes transiently noted in 11 patients and decreasing bone marrow cellularity noted in two while on treatment. Because of these effects, dosage adjustments were frequently instituted in the RA, RARS, and RAEB patients. The average dosages and durations of treatment received were thus 1.48 MU/M2 x 19.4 injections for patients with RA, RARS, and RAEB and 2.25 MU/M2 x 27 injections for the CMMoL patients. Progression to acute myeloid leukemia or RAEB in transformation was noted in five patients, and increasing leukocytosis was noted in one CMMoL patient while on protocol. It cannot be determined at this time whether these transformations were accelerated by α2 interferon or represent selection bias in this study population. Although some evidence of beneficial effects was noted, α2 interferon in this dosage and schedule is not a useful treatment for myelodysplastic syndromes.

UR - http://www.scopus.com/inward/record.url?scp=0023637564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023637564&partnerID=8YFLogxK

M3 - Article

VL - 1

SP - 105

EP - 110

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 2

ER -